Skip to main content
. 2022 Dec 9;2022(1):251-258. doi: 10.1182/hematology.2022000342

Figure 1.

Figure 1.

Risk of cardiomyopathy associated with (A) daunorubicin and (B) mitoxantrone relative to doxorubicin. Markers and extending 95% confidence intervals for each agent represents estimates from a Cox proportional hazards model based on categorical dose increments. Each marker is placed at the median dose on the x-axis for each category. Lines represent the linear (solid) and linear exponential (dashed) modeled continuous dose-response relationships. From Feijen et al.11,12